{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T15:49:59Z","timestamp":1791474599214,"version":"4.3.4"},"reference-count":28,"publisher":"Japanese Society of Internal Medicine","issue":"10","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Intern. Med."],"published-print":{"date-parts":[[2018,5,15]]},"DOI":"10.2169\/internalmedicine.9826-17","type":"journal-article","created":{"date-parts":[[2017,12,26]],"date-time":"2017-12-26T17:16:13Z","timestamp":1514308573000},"page":"1345-1353","source":"Crossref","is-referenced-by-count":35,"title":["The Safety and Efficacy of Combination Therapy of Sorafenib and Radiotherapy for Advanced Hepatocellular Carcinoma: A Retrospective Study"],"prefix":"10.2169","volume":"57","author":[{"given":"Yoshiyuki","family":"Wada","sequence":"first","affiliation":[{"name":"Department of Hepato-Biliary-Pancreatic Surgery, Clinical Research Institute, National Hospital Organization Kyushu Medical Center, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuko","family":"Takami","sequence":"additional","affiliation":[{"name":"Department of Hepato-Biliary-Pancreatic Surgery, Clinical Research Institute, National Hospital Organization Kyushu Medical Center, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hajime","family":"Matsushima","sequence":"additional","affiliation":[{"name":"Department of Hepato-Biliary-Pancreatic Surgery, Clinical Research Institute, National Hospital Organization Kyushu Medical Center, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masaki","family":"Tateishi","sequence":"additional","affiliation":[{"name":"Department of Hepato-Biliary-Pancreatic Surgery, Clinical Research Institute, National Hospital Organization Kyushu Medical Center, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomoki","family":"Ryu","sequence":"additional","affiliation":[{"name":"Department of Hepato-Biliary-Pancreatic Surgery, Clinical Research Institute, National Hospital Organization Kyushu Medical Center, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Munehiro","family":"Yoshitomi","sequence":"additional","affiliation":[{"name":"Department of Hepato-Biliary-Pancreatic Surgery, Clinical Research Institute, National Hospital Organization Kyushu Medical Center, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taisei","family":"Matsumura","sequence":"additional","affiliation":[{"name":"Department of Radiology, National Hospital Organization Kyushu Medical Center, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hideki","family":"Saitsu","sequence":"additional","affiliation":[{"name":"Department of Hepato-Biliary-Pancreatic Surgery, Clinical Research Institute, National Hospital Organization Kyushu Medical Center, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"962","reference":[{"key":"1","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1016\/S1470-2045(01)00486-7","volume":"2","author":"DM Parkin","year":"2001","unstructured":"1. Parkin DM. Global cancer statistics in the year 2000. The Lancet Oncology 2: 533-543, 2001.","journal-title":"The Lancet Oncology","ISSN":"https:\/\/id.crossref.org\/issn\/1470-2045","issn-type":"print"},{"key":"2","doi-asserted-by":"publisher","unstructured":"2. El-Serag HB, Rudolph KL. Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. Gastroenterology 132: 2557-2576, 2007.","DOI":"10.1053\/j.gastro.2007.04.061"},{"key":"3","doi-asserted-by":"crossref","first-page":"1907","DOI":"10.1016\/S0140-6736(03)14964-1","volume":"362","author":"JM Llovet","year":"2003","unstructured":"3. Llovet JM, Burroughs A, Bruix J. Hepatocellular carcinoma. Lancet 362: 1907-1917, 2003.","journal-title":"The Lancet","ISSN":"https:\/\/id.crossref.org\/issn\/0140-6736","issn-type":"print"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4. Wilhelm SM, Carter C, Tang L, et al. BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF\/MEK\/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res 64: 7099-7109, 2004.","DOI":"10.1158\/0008-5472.CAN-04-1443"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5. Llovet JM, Ricci S, Mazzaferro V, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 359: 378-390, 2008.","DOI":"10.1056\/NEJMoa0708857"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6. Cheng AL, Kang YK, Chen Z, et al. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol 10: 25-34, 2009.","DOI":"10.1016\/S1470-2045(08)70285-7"},{"key":"7","doi-asserted-by":"publisher","unstructured":"7. Bruix J, Sherman M. Management of hepatocellular carcinoma: an update. Hepatology 53: 1020-1022, 2011.","DOI":"10.1002\/hep.24199"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8. Park YJ, Lim DH, Paik SW, et al. Radiation therapy for abdominal lymph node metastasis from hepatocellular carcinoma. J Gastroenterol 41: 1099-1106, 2006.","DOI":"10.1007\/s00535-006-1895-x"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9. Zeng ZC, Tang ZY, Fan J, et al. Consideration of role of radiotherapy for lymph node metastases in patients with HCC: retrospective analysis for prognostic factors from 125 patients. Int J Radiat Oncol Biol Phys 63: 1067-1076, 2005.","DOI":"10.1016\/j.ijrobp.2005.03.058"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10. Chen YX, Zeng ZC, Fan J, et al. Defining prognostic factors of survival after external beam radiotherapy treatment of hepatocellular carcinoma with lymph node metastases. Clin Transl Oncol 15: 732-740, 2013.","DOI":"10.1007\/s12094-012-0997-6"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11. Minagawa M, Makuuchi M. Treatment of hepatocellular carcinoma accompanied by portal vein tumor thrombus. World J Gastroenterol 12: 7561-7567, 2006.","DOI":"10.3748\/wjg.v12.i47.7561"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12. Xi M, Zhang L, Zhao L, et al. Effectiveness of stereotactic body radiotherapy for hepatocellular carcinoma with portal vein and\/or inferior vena cava tumor thrombosis. PLoS One 8: e63864, 2013.","DOI":"10.1371\/journal.pone.0063864"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13. Tanaka Y, Nakazawa T, Komori S, et al. Radiotherapy for patients with unresectable advanced hepatocellular carcinoma with invasion to intrahepatic large vessels: efficacy and outcomes. J Gastroenterol Hepatol 29: 352-357, 2014.","DOI":"10.1111\/jgh.12333"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14. Cha J, Seong J, Lee IJ, Kim JW, Han KH. Feasibility of sorafenib combined with local radiotherapy in advanced hepatocellular carcinoma. Yonsei Med J 54: 1178-1185, 2013.","DOI":"10.3349\/ymj.2013.54.5.1178"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15. Lee DY, Park JW, Kim TH, et al. Prognostic indicators for radiotherapy of abdominal lymph node metastases from hepatocellular carcinoma. Strahlenther Onkol 191: 835-844, 2015.","DOI":"10.1007\/s00066-015-0873-8"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16. Zhao JD, Liu J, Ren ZG, et al. Maintenance of Sorafenib following combined therapy of three-dimensional conformal radiation therapy\/intensity-modulated radiation therapy and transcatheter arterial chemoembolization in patients with locally advanced hepatocellular carcinoma: a phase I\/II study. Radiat Oncol 5: 12, 2010.","DOI":"10.1186\/1748-717X-5-12"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17. European Association For The Study Of The L; European Organisation For Research And Treatment Of Cancer. EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma. J Hepatol 56: 908-943, 2012.","DOI":"10.1016\/j.jhep.2011.12.001"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18. Lencioni R, Llovet JM. Modified RECIST (mRECIST) assessment for hepatocellular carcinoma. Semin Liver Dis 30: 52-60, 2010.","DOI":"10.1055\/s-0030-1247132"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19. Stillwagon GB, Order SE, Guse C, et al. 194 hepatocellular cancers treated by radiation and chemotherapy combinations: toxicity and response: a Radiation Therapy Oncology Group Study. Int J Radiat Oncol Biol Phys 17: 1223-1229, 1989.","DOI":"10.1016\/0360-3016(89)90530-0"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20. Robertson JM, McGinn CJ, Walker S, et al. A phase I trial of hepatic arterial bromodeoxyuridine and conformal radiation therapy for patients with primary hepatobiliary cancers or colorectal liver metastases. Int J Radiat Oncol Biol Phys 39: 1087-1092, 1997.","DOI":"10.1016\/S0360-3016(97)00550-6"},{"key":"21","doi-asserted-by":"crossref","unstructured":"21. Mohiuddin M, Chen E, Ahmad N. Combined liver radiation and chemotherapy for palliation of hepatic metastases from colorectal cancer. J Clin Oncol 14: 722-728, 1996.","DOI":"10.1200\/JCO.1996.14.3.722"},{"key":"22","doi-asserted-by":"crossref","first-page":"79","DOI":"10.4143\/crt.2004.36.1.79","volume":"36","author":"SM Yoon","year":"2004","unstructured":"22. Yoon SM, Kim JH, Choi EK, et al. Radioresponse of hepatocellular carcinoma-treatment of lymph node metastasis. Cancer Research and Treatment 36: 79-84, 2004.","journal-title":"Cancer Research and Treatment","ISSN":"https:\/\/id.crossref.org\/issn\/1598-2998","issn-type":"print"},{"key":"23","doi-asserted-by":"crossref","unstructured":"23. Kim K, Chie EK, Kim W, et al. Absence of symptom and intact liver function are positive prognosticators for patients undergoing radiotherapy for lymph node metastasis from hepatocellular carcinoma. Int J Radiat Oncol Biol Phys 78: 729-734, 2010.","DOI":"10.1016\/j.ijrobp.2009.08.047"},{"key":"24","doi-asserted-by":"crossref","unstructured":"24. Yamashita H, Nakagawa K, Shiraishi K, et al. Radiotherapy for lymph node metastases in patients with hepatocellular carcinoma: retrospective study. J Gastroenterol Hepatol 22: 523-527, 2007.","DOI":"10.1111\/j.1440-1746.2006.04450.x"},{"key":"25","doi-asserted-by":"crossref","unstructured":"25. Nakazawa T, Hidaka H, Shibuya A, et al. Overall survival in response to sorafenib versus radiotherapy in unresectable hepatocellular carcinoma with major portal vein tumor thrombosis: propensity score analysis. BMC Gastroenterol 14: 84, 2014.","DOI":"10.1186\/1471-230X-14-84"},{"key":"26","doi-asserted-by":"publisher","unstructured":"26. Uchino K, Tateishi R, Shiina S, et al. Hepatocellular carcinoma with extrahepatic metastasis: clinical features and prognostic factors. Cancer 117: 4475-4483, 2011.","DOI":"10.1002\/cncr.25960"},{"key":"27","doi-asserted-by":"crossref","unstructured":"27. Plastaras JP, Kim SH, Liu YY, et al. Cell cycle dependent and schedule-dependent antitumor effects of sorafenib combined with radiation. Cancer Res 67: 9443-9454, 2007.","DOI":"10.1158\/0008-5472.CAN-07-1473"},{"key":"28","doi-asserted-by":"crossref","unstructured":"28. Kaneko S, Ikeda K, Matsuzaki Y, et al. Safety and effectiveness of sorafenib in Japanese patients with hepatocellular carcinoma in daily medical practice: interim analysis of a prospective postmarketing all-patient surveillance study. J Gastroenterol 51: 1011-1021, 2016.","DOI":"10.1007\/s00535-016-1173-5"}],"container-title":["Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/57\/10\/57_9826-17\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2018,5,18]],"date-time":"2018-05-18T23:59:00Z","timestamp":1526687940000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/57\/10\/57_9826-17\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,5,15]]},"references-count":28,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2018]]}},"URL":"https:\/\/doi.org\/10.2169\/internalmedicine.9826-17","relation":{},"ISSN":["0918-2918","1349-7235"],"issn-type":[{"value":"0918-2918","type":"print"},{"value":"1349-7235","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,5,15]]}}}